Novo Nordisk India has announced a partnership with Pune-based Emcure Pharmaceuticals to launch Poviztra® (semaglutide injection 2.4 mg), a new weight-loss medicine in India. Poviztra® will be marketed as the second brand of Wegovy®, Novo Nordisk’s globally approved drug for chronic weight management.
Under this deal, Emcure Pharma will have exclusive rights to distribute and sell Poviztra® in India. The collaboration aims to make Novo Nordisk’s obesity treatment more accessible to people across the country.
Wegovy®, launched in India in June 2025, helps adults with obesity or overweight reduce body weight when combined with a healthy diet and physical activity. Clinical trials have shown that one in three people using Wegovy® lost more than 20% of their body weight.
“Obesity is a serious health issue in India. This partnership will help expand access to safe and effective obesity treatments,” said Jay Thyagarajan, Senior Vice President, Region APAC, Novo Nordisk.
Satish Mehta, CEO and Managing Director of Emcure Pharmaceuticals, added, “We are proud to partner with Novo Nordisk to bring Poviztra® to India. Our goal is to make this trusted medicine available to patients who need it the most.”
Semaglutide, the active ingredient in Poviztra® and Wegovy®, has been used globally for nearly a decade and is supported by strong clinical data. The medicine will be available as a once-weekly injection in different dose strengths, offering a convenient treatment option for people with obesity.
India currently has over 250 million people living with obesity, highlighting the growing need for effective and accessible weight management solutions.